Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients
Status:
Terminated
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if temsirolimus can help to control
advanced cancer in patients who also have a PI3K mutation and/or PTEN loss. The safety of
this drug will also be tested.